The R&D World Index saw gains this week, driven partly by a surge in Intel’s value amid significant developments across various sectors. Honda and Nissan have ended their merger talks, citing concerns over autonomy and decision-making, while GlaxoSmithKline consolidates its vaccine R&D in Cambridge, MA. Novartis is set to reacquire rights to a blood clot…
In 2024, the US and Europe led in pharma value creation while GLP-1s disrupted the landscape
GLP-1 juggernauts Eli Lilly and Novo Nordisk, whose combined $1.18 trillion market cap now exceeds Johnson & Johnson, AbbVie, and Merck combined, have staked their claim as stock market darlings. This momentum is particularly evident in Novo Nordisk’s remarkable trajectory, reaching a $604 billion market capitalization by March 2024 and securing its position as the…
R&D Market Pulse: NVIDIA hits $37.5B in revenue while UK regulators tap brakes on AI startup investment oversight
In a move signaling a more relaxed regulatory approach to the booming AI sector, UK regulators announced they would not investigate Google’s $2 billion investment in AI startup Anthropic. The move mirrors a similar decision regarding Amazon’s earlier $4 billion stake. This green light comes as Amazon doubles, bringing its total investment in Anthropic to…